Diego Villa, MD, MPH

home / authors / diego-villa-md-mph

Articles

Dr. Villa on Rationale for Examining BR as Induction Therapy in Transplant-Eligible MCL

May 13th 2020

Diego Villa, MD, MPH, discusses the rationale for a retrospective analysis evaluating bendamustine plus rituximab as induction therapy in patients with mantle cell lymphoma.

Dr. Villa on the Use of BR as Induction Therapy in MCL

Diego Villa, MD, MPH

April 9th 2020

Diego Villa, MD, MPH, clinical associate professor, Division of Medical Oncology, Department of Medicine, The University of British Columbia, discusses the use of bendamustine and rituximab (Rituxan) as induction therapy in mantle cell lymphoma (MCL).

Dr. Villa on Retrospective Data of Bendamustine/Rituximab in MCL

Diego Villa, MD, MPH

March 10th 2020

Diego Villa, MD, MPH, discusses the findings of a retrospective analysis looking at bendamustine plus rituximab in mantle cell lymphoma.

Dr. Villa on the Efficacy of Induction Therapy With BR in MCL

Diego Villa, MD, MPH

February 5th 2020

Diego Villa, MD, MPH, clinical associate professor, Division of Medical Oncology, Department of Medicine, The University of British Columbia, discusses the efficacy of induction therapy with bendamustine plus rituximab (Rituxan) in mantle cell lymphoma (MCL).

Dr. Villa on Induction Therapy With Bendamustine/Rituximab in MCL

Diego Villa, MD, MPH

January 15th 2020

Diego Villa, MD, MPH, discusses a retrospective analysis of bendamustine and rituximab as induction therapy in patients with transplant-eligible and -ineligible mantle cell lymphoma.